The role of thrombolytic therapy in pulmonary embolism

Blood

Volumn 125, Issue 14, 2015, Pages 2191-2199

  Wang, Tzu Fei ^a   Squizzato, Alessandro ^b   Dentali, Francesco ^b   Ageno, Walter ^b  

^a OHIO STATE UNIVERSITY   (United States)

^b UNIVERSITY OF INSUBRIA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

FIBRINOLYTIC AGENT; TROPONIN;

ADULT; ANTICOAGULANT THERAPY; CASE REPORT; COMPUTER ASSISTED TOMOGRAPHY; DYSPNEA; ECHOCARDIOGRAPHY; FIBRINOLYTIC THERAPY; HEART RATE; HEART RIGHT VENTRICLE PRESSURE; HUMAN; HYPOXIA; IMMOBILIZATION; LUNG EMBOLISM; MALE; MEDICAL HISTORY; OXYGEN SATURATION; PATIENT HISTORY OF SURGERY; PRIORITY JOURNAL; PULMONARY ARTERY EMBOLISM; REVIEW; RISK FACTOR; SYSTOLIC BLOOD PRESSURE; TACHYPNEA; THORAX PAIN; TRICUSPID VALVE; EVIDENCE BASED MEDICINE; PULMONARY EMBOLISM;

EVIDENCE-BASED MEDICINE; FIBRINOLYTIC AGENTS; HUMANS; PULMONARY EMBOLISM; THROMBOLYTIC THERAPY;

EID: 84926688248     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2014-08-559278     Document Type: Review

References (46)

1. Beckman MG, Hooper WC, Critchley S.E., Ortel TL. Venous thromboembolism: a public health concern. Am J Prev Med. 2010; 38(4 Suppl): S495-S501.
2. Cushman M, Tsai AW, White R.H., et al. Deep vein thrombosis and pulmonary embolism in two cohorts: the longitudinal investigation of thromboembolism etiology. Am J Med. 2004; 117(1):19-25.
3. Stein PD, Kayali F, Olson RE Estimated case fatality rate of pulmonary embolism, 1979 to 1998. Am J Cardiol. 2004; 93(9):1197-1199.
4. Centers for Disease Control and Prevention (CDC). Venous thromboembolism in adult hospitalizations - United States, 2007-2009. MMWR Morb Mortal Wkly Rep. 2012; 61(22): 401-404.
5. Nakamura S, Takano H, Kubota Y., Asai K, Shimizu W. Impact of the efficacy of thrombolytic therapy on the mortality of patients with acute submassive pulmonary embolism: a metaanalysis. J Thromb Haemost. 2014; 12(7): 1086-1095.
6. Marti C, John G, Konstantinides S., et al. Systemic thrombolytic therapy for acute pulmonary embolism: a systematic review and meta-analysis [published online ahead of print June 10, 2014]. Eur Heart J.
7. Chatterjee S, Chakraborty A, Weinberg I., et al. Thrombolysis for pulmonary embolism and risk of all-cause mortality, major bleeding, and intracranial hemorrhage: a meta-analysis. JAMA. 2014; 311(23):2414-2421.
8. Cao Y, Zhao H, Gao W., Wang Y, Cao J. Systematic review and meta-analysis for thrombolysis treatment in patients with acute submassive pulmonary embolism. Patient Prefer Adherence. 2014; 8:275-282.
9. Higgins JPT, Green S, eds. Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0. The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.
10. Urokinase pulmonary embolism trial. Phase 1 results: a cooperative study. JAMA. 1970; 214(12):2163-2172.
11. Tibbutt DA, Davies JA, Anderson J.A., et al. Comparison by controlled clinical trial of streptokinase and heparin in treatment of life-threatening pulmonay embolism. BMJ. 1974; 1(5904):343-347.
12. Ly B, Arnesen H, Eie H., Hol R. A controlled clinical trial of streptokinase and heparin in the treatment of major pulmonary embolism. Acta Med Scand. 1978; 203(6):465-470.
13. Dotter CT, Seaman AJ, Rosch J, Rorter JM Streptokinase and heparin in the treatment of pulmonary embolism: a randomized comparison. Vasc Endovascular Surg. 1979; 13(1):42-52.
14. Marini C, Di Ricco G, Rossi G, Rindi M., Palla R, Giuntini C. Fibrinolytic effects of urokinase and heparin in acute pulmonary embolism: a randomized clinical trial. Respiration. 1988; 54(3):162-173.
15. Levine M, Hirsh J, Weitz J., et al. A randomized trial of a single bolus dosage regimen of recombinant tissue plasminogen activator in patients with acute pulmonary embolism. Chest. 1990; 98(6):1473-1479.
16. PIOPED. Tissue plasminogen activator for the treatment of acute pulmonary embolism. A collaborative study by the PIOPED Investigators. Chest. 1990; 97(3):528-533.
17. Dalla-Volta S., Palla A, Santolicandro A., et al. PAIMS 2: alteplase combined with heparin versus heparin in the treatment of acute pulmonary embolism. Plasminogen activator Italian multicenter study 2. J Am Coll Cardiol. 1992; 20(3):520-526.
18. Goldhaber SZ, Haire WD, Feldstein M.L., et al. Alteplase versus heparin in acute pulmonary embolism: randomised trial assessing right-ventricular function and pulmonary perfusion. Lancet. 1993; 341(8844):507-511.
19. Jerjes-Sanchez C., Ramírez-Rivera A, Arriaga-Nava R, et al; de Lourdes García M. Streptokinase and Heparin versus Heparin Alone in Massive Pulmonary Embolism: A Randomized Controlled Trial. J Thromb Thrombolysis. 1995; 2(3):227-229.
20. Konstantinides S, Geibel A, Heusel G., Heinrich F, Kasper W; Management Strategies and Prognosis of Pulmonary Embolism-3 Trial Investigators. Heparin plus alteplase compared with heparin alone in patients with submassive pulmonary embolism. N Engl J Med. 2002; 347(15):1143-1150.
21. Becattini C, Agnelli G, Salvi A., et al; TIPES Study Group. Bolus tenecteplase for right ventricle dysfunction in hemodynamically stable patients with pulmonary embolism. Thromb Res. 2010; 125(3):e82-e86.
22. Fasullo S, Scalzo S, Maringhini G., et al. Six-month echocardiographic study in patients with submassive pulmonary embolism and right ventricle dysfunction: comparison of thrombolysis with heparin. Am J Med Sci. 2011; 341(1):33-39.
23. Sharifi M, Bay C, Skrocki L., Rahimi F, Mehdipour M, Investigators M; "MOPETT" Investigators. Moderate pulmonary embolism treated with thrombolysis (from the "MOPETT" Trial). Am J Cardiol. 2013; 111(2):273-277.
24. Kline JA, Nordenholz KE, Courtney D.M., et al. Treatment of submassive pulmonary embolism with tenecteplase or placebo: cardiopulmonary outcomes at 3 months: multicenter double-blind, placebo-controlled randomized trial. J Thromb Haemost. 2014; 12(4):459-468.
25. Meyer G, Vicaut E, Danays T., et al; PEITHO Investigators. Fibrinolysis for patients with intermediate-risk pulmonary embolism. N Engl J Med. 2014; 370(15):1402-1411.
26. Urokinase-streptokinase embolism trial. Phase 2 results. A cooperative study. JAMA. 1974; 229(12):1606-1613.
27. The UKEP Study Research Group. The UKEP study: multicentre clinical trial on two local regimens of urokinase in massive pulmonary embolism. Eur Heart J. 1987; 8(1):2-10.
28. Verstraete M, Miller GA, Bounameaux H, et al Intravenous and intrapulmonary recombinant tissue-type plasminogen activator in the treatment of acute massive pulmonary embolism. Circulation. 1988; 77(2):353-360.
29. Goldhaber SZ, Kessler CM, Heit J, et al Randomised controlled trial of recombinant tissue plasminogen activator versus urokinase in the treatment of acute pulmonary embolism. Lancet. 1988; 332(8606):293-298.
30. Goldhaber SZ, Kessler CM, Heit J.A., et al. Recombinant tissue-type plasminogen activator versus a novel dosing regimen of urokinase in acute pulmonary embolism: a randomized controlled multicenter trial. J Am Coll Cardiol. 1992; 20(1):24-30.
31. Meyer G, Sors H, Charbonnier B., et al; The European Cooperative Study Group for Pulmonary Embolism. Effects of intravenous urokinase versus alteplase on total pulmonary resistance in acute massive pulmonary embolism: a European multicenter double-blind trial. J Am Coll Cardiol. 1992; 19(2):239-245.
32. Goldhaber SZ, Agnelli G, Levine MN; The Bolus Alteplase Pulmonary Embolism Group. Reduced dose bolus alteplase vs conventional alteplase infusion for pulmonary embolism thrombolysis. An international multicenter randomized trial. Chest. 1994; 106(3):718-724.
33. Sors H, Pacouret G, Azarian R., Meyer G, Charbonnier B, Simonneau G. Hemodynamic effects of bolus vs 2-h infusion of alteplase in acute massive pulmonary embolism. A randomized controlled multicenter trial. Chest. 1994; 106(3):712-717.
34. Meneveau N, Schiele F, Vuillemenot A., et al. Streptokinase vs alteplase in massive pulmonary embolism. A randomized trial assessing right heart haemodynamics and pulmonary vascular obstruction. Eur Heart J. 1997; 18(7):1141-1148.
35. Meneveau N, Schiele F, Metz D., et al. Comparative efficacy of a two-hour regimen of streptokinase versus alteplase in acute massive pulmonary embolism: immediate clinical and hemodynamic outcome and one-year follow-up. J Am Coll Cardiol. 1998; 31(5):1057-1063.
36. Tebbe U, Graf A, Kamke W., et al. Hemodynamic effects of double bolus reteplase versus alteplase infusion in massive pulmonary embolism. Am Heart J. 1999; 138(1):39-44.
37. Tebbe U, Bramlage P, Graf A., et al. Desmoteplase in acute massive pulmonary thromboembolism. Thromb Haemost. 2009; 101(3):557-562.
38. Wang C, Zhai Z, Yang Y., et al; China Venous Thromboembolism Study Group. Efficacy and safety of 2-hour urokinase regime in acute pulmonary embolism: a randomized controlled trial. Respir Res. 2009; 10:128.
39. Yang Y, Wang C, Wang Y. Recombinant streptokinase versus urokinase in pulmonary embolism: a randomized, multi-center, controlled trial [abstract]. Am J Respir Crit Care Med. 2010; 181. Abstract:1922.
40. Wang C, Zhai Z, Yang Y., et al; China Venous Thromboembolism (VTE) Study Group. Efficacy and safety of low dose recombinant tissue-type plasminogen activator for the treatment of acute pulmonary thromboembolism: a randomized, multicenter, controlled trial. Chest. 2010; 137(2): 254-262.
41. Abdelsamad AA, El-Morsi AS, Mansour AE. Efficacy and safety of high dose versus low dose streptokinase for treatment of submassive pulmonary embolism. Egypt Heart J. 2011; 63(2):67-72.
42. Kucher N, Boekstegers P, Müller OJ, et al. Randomized, controlled trial of ultrasound-assisted catheter-directed thrombolysis for acute intermediate-risk pulmonary embolism. Circulation. 2014; 129(4):479-486.
43. Konstantinides SV, Torbicki A, Agnelli G., et al. 2014 ESC guidelines on the diagnosis and management of acute pulmonary embolism: The Task Force for the Diagnosis and Management of Acute Pulmonary Embolism of the European Society of Cardiology (ESC) endorsed by the European Respiratory Society (ERS). Eur Heart J. 2014; 35(43):3033-3073.
44. Zhang Z, Zhai ZG, Liang L.R., Liu FF, Yang YH, Wang C. Lower dosage of recombinant tissuetype plasminogen activator (rt-PA) in the treatment of acute pulmonary embolism: a systematic review and meta-analysis. Thromb Res. 2014; 133(3):357-363.
45. Kuo WT, Gould MK, Louie J.D., Rosenberg JK, Sze DY, Hofmann LV. Catheter-directed therapy for the treatment of massive pulmonary embolism: systematic review and meta-analysis of modern techniques. J Vasc Interv Radiol. 2009; 20(11): 1431-1440.
46. Deeks JJ, Higgins JPT, Altman DG, on behalf of the Cochrane Statistical Methods Group. In: Higgins JPT, Green S, eds. Cochrane Handbook for Systematic Reviews of Interventions. Oxford: John Wiley & Sons; 2008:244-275.